Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Seroprevalence of novel coronavirus disease (COVID-19) in Kobe, Japan

Asako Doi, View ORCID ProfileKentaro Iwata, Hirokazu Kuroda, Toshikazu Hasuike, Seiko Nasu, Aya Kanda, Tomomi Nagao, Hiroaki Nishioka, Keisuke Tomii, Takeshi Morimoto, Yasuki Kihara
doi: https://doi.org/10.1101/2020.04.26.20079822
Asako Doi
1Department of Infection Control, Kobe City Medical Center General Hospital, Chuoku 6500047, Kobe, Hyogo, Japan
2Department of Infectious Diseases, Kobe City Medical Center General Hospital, Chuoku 6500047, Kobe, Hyogo, Japan
3Division of Infectious Diseases Therapeutics, Kobe University Graduate School of Medicine, Chuoku 6500017, Kobe, Hyogo, Japan
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kentaro Iwata
3Division of Infectious Diseases Therapeutics, Kobe University Graduate School of Medicine, Chuoku 6500017, Kobe, Hyogo, Japan
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Kentaro Iwata
  • For correspondence: asakodoi{at}gmail.com
Hirokazu Kuroda
1Department of Infection Control, Kobe City Medical Center General Hospital, Chuoku 6500047, Kobe, Hyogo, Japan
2Department of Infectious Diseases, Kobe City Medical Center General Hospital, Chuoku 6500047, Kobe, Hyogo, Japan
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Toshikazu Hasuike
1Department of Infection Control, Kobe City Medical Center General Hospital, Chuoku 6500047, Kobe, Hyogo, Japan
2Department of Infectious Diseases, Kobe City Medical Center General Hospital, Chuoku 6500047, Kobe, Hyogo, Japan
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Seiko Nasu
1Department of Infection Control, Kobe City Medical Center General Hospital, Chuoku 6500047, Kobe, Hyogo, Japan
4Department of Laboratory Medicine, Kobe City Medical Center General Hospital, Chuoku 6500047, Kobe, Hyogo, Japan
MT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aya Kanda
4Department of Laboratory Medicine, Kobe City Medical Center General Hospital, Chuoku 6500047, Kobe, Hyogo, Japan
MT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tomomi Nagao
4Department of Laboratory Medicine, Kobe City Medical Center General Hospital, Chuoku 6500047, Kobe, Hyogo, Japan
MT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hiroaki Nishioka
2Department of Infectious Diseases, Kobe City Medical Center General Hospital, Chuoku 6500047, Kobe, Hyogo, Japan
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Keisuke Tomii
5Department of Pulmonary Medicine, Kobe City Medical Center General Hospital, Chuoku 6500047, Kobe, Hyogo, Japan
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takeshi Morimoto
6Department of Clinical Epidemiology, Hyogo Medical College, Mukogawa 6638501, Nishinomiya, Hyogo, Japan
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yasuki Kihara
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Coronavirus disease 2019 (COVID-19) pandemic caused by SARS-CoV-2 has been affecting many people on earth and our society. Japan is known to have relatively less number of infections as well as deaths among developed nations. However, accurate prevalence of COVID-19 in Japan remains unknown. Therefore, we conducted a cross-sectional study to estimate seroprevalence of SARS-CoV-2 infection.

Methods We conducted a cross-sectional serologic testing for SARS-CoV-2 antibody using 1,000 samples from patients at outpatient settings who visited the clinic from March 31 to April 7, 2020, stratified by the decade of age and sex.

Results There were 33 positive IgG among 1,000 serum samples (3.3%, 95%CI: 2.3-4.6%). By applying this figure to the census of Kobe City (population: 1,518,870), it is estimated that the number of people with positive IgG be 50,123 (95%CI: 34,934-69,868). Age and sex adjusted prevalence of positivity was calculated 2.7% (95%CI: 1.8-3.9%), and the estimated number of people with positive IgG was 40,999 (95%CI: 27,333-59,221). These numbers were 396 to 858 fold more than confirmed cases with PCR testing in Kobe City.

Conclusions Our cross-sectional serological study suggests that the number of people with seropositive for SARS-CoV-2 infection in Kobe, Japan is far more than the confirmed cases by PCR testing.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

The study was conducted using unrestricted research funds of Division of Infectious Diseases Therapeutics, Kobe University Graduate School of Medicine, provided by Tsumura & Co. and Takasago Seibu Hospital.

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Data is available upon request.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted May 01, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Seroprevalence of novel coronavirus disease (COVID-19) in Kobe, Japan
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Seroprevalence of novel coronavirus disease (COVID-19) in Kobe, Japan
Asako Doi, Kentaro Iwata, Hirokazu Kuroda, Toshikazu Hasuike, Seiko Nasu, Aya Kanda, Tomomi Nagao, Hiroaki Nishioka, Keisuke Tomii, Takeshi Morimoto, Yasuki Kihara
medRxiv 2020.04.26.20079822; doi: https://doi.org/10.1101/2020.04.26.20079822
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Seroprevalence of novel coronavirus disease (COVID-19) in Kobe, Japan
Asako Doi, Kentaro Iwata, Hirokazu Kuroda, Toshikazu Hasuike, Seiko Nasu, Aya Kanda, Tomomi Nagao, Hiroaki Nishioka, Keisuke Tomii, Takeshi Morimoto, Yasuki Kihara
medRxiv 2020.04.26.20079822; doi: https://doi.org/10.1101/2020.04.26.20079822

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (434)
  • Allergy and Immunology (760)
  • Anesthesia (222)
  • Cardiovascular Medicine (3316)
  • Dentistry and Oral Medicine (366)
  • Dermatology (282)
  • Emergency Medicine (480)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1175)
  • Epidemiology (13403)
  • Forensic Medicine (19)
  • Gastroenterology (900)
  • Genetic and Genomic Medicine (5182)
  • Geriatric Medicine (483)
  • Health Economics (786)
  • Health Informatics (3286)
  • Health Policy (1146)
  • Health Systems and Quality Improvement (1199)
  • Hematology (432)
  • HIV/AIDS (1024)
  • Infectious Diseases (except HIV/AIDS) (14657)
  • Intensive Care and Critical Care Medicine (917)
  • Medical Education (478)
  • Medical Ethics (128)
  • Nephrology (526)
  • Neurology (4957)
  • Nursing (263)
  • Nutrition (735)
  • Obstetrics and Gynecology (889)
  • Occupational and Environmental Health (797)
  • Oncology (2531)
  • Ophthalmology (730)
  • Orthopedics (284)
  • Otolaryngology (348)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (547)
  • Pediatrics (1308)
  • Pharmacology and Therapeutics (552)
  • Primary Care Research (559)
  • Psychiatry and Clinical Psychology (4225)
  • Public and Global Health (7526)
  • Radiology and Imaging (1717)
  • Rehabilitation Medicine and Physical Therapy (1022)
  • Respiratory Medicine (982)
  • Rheumatology (480)
  • Sexual and Reproductive Health (500)
  • Sports Medicine (425)
  • Surgery (551)
  • Toxicology (73)
  • Transplantation (237)
  • Urology (206)